AKT1 and prostate cancer: Treatment of prostate cancer cells with the Epac agonist 8-CPT-2Me-cAMP upregulates Epac1 expression, Rap1 activation, MAPK activation, Akt phosphorylation at T308 and S473 in a PI 3-kinase dependent and mTORC1 and mTORC2 activation as judged by phosphorylation of S6-kinase at T389, 4EBP1 at T37/36 and Akt at S473 residues, respectively [47], .